Sindy T. Kim

14.2k total citations · 5 hit papers
22 papers, 10.9k citations indexed

About

Sindy T. Kim is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Sindy T. Kim has authored 22 papers receiving a total of 10.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 11 papers in Molecular Biology and 11 papers in Oncology. Recurrent topics in Sindy T. Kim's work include Renal cell carcinoma treatment (14 papers), Renal and related cancers (8 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Sindy T. Kim is often cited by papers focused on Renal cell carcinoma treatment (14 papers), Renal and related cancers (8 papers) and Pancreatic and Hepatic Oncology Research (5 papers). Sindy T. Kim collaborates with scholars based in United States, Germany and France. Sindy T. Kim's co-authors include Robert J. Motzer, M. Dror Michaelson, Robert A. Figlin, Ronald M. Bukowski, Charles M. Baum, Isan Chen, Thomas E. Hutson, Sylvie Négrier, Cezary Szczylik and Piotr Tomczak and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Sindy T. Kim

22 papers receiving 10.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 4.5k citations Robert J. Motzer, Thomas E. Hutson et al. New England Journal of Medicine profile →
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

2014 1.4k citations Richard S. Finn, John Crown et al. The Lancet Oncology profile →
Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

2005 1.3k citations Robert J. Motzer, M. Dror Michaelson et al. Journal of Clinical Oncology profile →
Sunitinib in Patients With Metastatic Renal Cell Carcinoma

2006 969 citations Robert J. Motzer, Brian I. Rini et al. JAMA profile →

Peers

Countries citing papers authored by Sindy T. Kim

Since Specialization

Citations

This map shows the geographic impact of Sindy T. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sindy T. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sindy T. Kim more than expected).

Fields of papers citing papers by Sindy T. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sindy T. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sindy T. Kim. The network helps show where Sindy T. Kim may publish in the future.

Co-authorship network of co-authors of Sindy T. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Sindy T. Kim. A scholar is included among the top collaborators of Sindy T. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sindy T. Kim. Sindy T. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma 2023 ·Journal of Clinical Oncology ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin	11
2	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 2016 ·Breast Cancer Research ·Richard S. Finn, John Crown, Johannes Ettl, Marcus Schmidt, Igor Bondarenko, István Láng, Tamás Pintér, Katalin Boér, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett, Dennis J. Slamon	136
3	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study breakdown → 2014 ·The Lancet Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Camilla Fowst, Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	1412
4	Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18) 2014 ·Cancer Research ·Richard S. Finn, John Crown, István Láng, Katalin Boér, Igor Bondarenko, (unknown), Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, (unknown), Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon	37
5	Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma 2013 ·Cancer Chemotherapy and Pharmacology ·Charles S. Harmon, Samuel E. DePrimo, Robert A. Figlin, Gary R. Hudes, Thomas E. Hutson, M. Dror Michaelson, Sylvie Négrier, Sindy T. Kim, Xin Huang, James A. Williams, Tim Eisen, Robert J. Motzer	47
6	Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth 2012 ·Clinical Cancer Research ·Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, Susan E. Bates	55
7	Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer 2011 ·Lung Cancer ·Radj Gervais, John D. Hainsworth, Normand Blais, Benjamin Besse, Janessa Laskin, John Hamm, Allan Lipton, Kathy S. Albain, Gregory A. Masters, Ronald B. Natale, Paulina Selaru, Sindy T. Kim, Richard C. Chao, Ray D. Page	14
8	Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results 2010 ·Cancer Chemotherapy and Pharmacology ·Elisabeth I. Heath, George R. Blumenschein, Roger B. Cohen, Patricia LoRusso, Noelle K. LoConte, Sindy T. Kim, Ana Ruiz-Garcı́a, Richard C. Chao, George Wilding	12
9	Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma 2010 ·American Journal of Clinical Oncology ·Robert J. Motzer, Gary R. Hudes, Michelle S. Ginsberg, Michael Baum, Charles S. Harmon, Sindy T. Kim, Isan Chen, Bruce G. Redman	22
10	A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma 2010 ·Blood ·Rubén Niesvizky, Suzanne Lentzsch, Ashraf Badros, Asher Chanan‐Khan, Seema Singhal, Jeffrey A. Zonder, Ravi Vij, Xiangao Huang, Maurizio DiLiberto, Rachel Courtney, M. Naveed Shaik, Sindy T. Kim, Sophia Randolph, Scott Ely, Selina Chen‐Kiang	11
11	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma breakdown → 2009 ·Journal of Clinical Oncology ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin	1711
12	Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa 2009 ·Journal of Oncology Practice ·David Cella, Joseph C. Cappelleri, Andrew G. Bushmakin, Claudie Charbonneau, Jim Z. Li, Sindy T. Kim, Isan Chen, M. Dror Michaelson, Robert J. Motzer	34
13	Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma 2008 ·Journal of Clinical Oncology ·Brian I. Rini, M. Dror Michaelson, Jonathan E. Rosenberg, Ronald M. Bukowski, Jeffrey A. Sosman, Walter M. Stadler, Thomas E. Hutson, Kim Margolin, Charles S. Harmon, Samuel E. DePrimo, Sindy T. Kim, Isan Chen, Daniel J. George	321
14	Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma 2008 ·Cancer ·Robert J. Motzer, Ronald M. Bukowski, Robert A. Figlin, Thomas E. Hutson, M. Dror Michaelson, Sindy T. Kim, Charles M. Baum, Michael W. Kattan	162
15	Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy–Kidney Symptom Index—Disease-Related Symptoms Scale 2008 ·Value in Health ·Xuemei Luo, Joseph C. Cappelleri, David Cella, Jim Z. Li, Claudie Charbonneau, Sindy T. Kim, Isan Chen, Robert J. Motzer	7
16	Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma 2008 ·Journal of Clinical Oncology ·Edit Remák, Claudie Charbonneau, Sylvie Négrier, Sindy T. Kim, Robert J. Motzer	77
17	Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma breakdown → 2007 ·New England Journal of Medicine ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul Bycott, Charles M. Baum, Robert A. Figlin	4471
18	Patients with Metastatic Renal Cell Carcinoma with Long-Term Disease-Free Survival After Treatment with Sunitinib and Resection of Residual Metastases 2006 ·Clinical Genitourinary Cancer ·Brian I. Rini, Vanessa Shaw, Jonathan E. Rosenberg, Sindy T. Kim, Isan Chen	30
19	Sunitinib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·JAMA ·Robert J. Motzer, Brian I. Rini, Ronald M. Bukowski, Brendan D. Curti, Daniel J. George, Gary R. Hudes, Bruce G. Redman, Kim Margolin, Jaime R. Merchan, George Wilding, Michelle S. Ginsberg, Jennifer Bacik, Sindy T. Kim, Charles M. Baum, M. Dror Michaelson	969
20	Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma breakdown → 2005 ·Journal of Clinical Oncology ·Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman, Gary R. Hudes, George Wilding, Robert A. Figlin, Michelle S. Ginsberg, Sindy T. Kim, Charles M. Baum, Samuel E. DePrimo, Jim Z. Li, Carlo L. Bello, Charles P. Theuer, Daniel J. George, Brian I. Rini	1304

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact